Monoaminergic Antidepressants in the Relief of Pain: Potential Therapeutic Utility of Triple Reuptake Inhibitors (TRIs).

about

Monoaminergic Antidepressants in the Relief of Pain: Potential Therapeutic Utility of Triple Reuptake Inhibitors (TRIs).

Item

http://www.wikidata.org/entity/Q55421497

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Monoaminergic Antidepressants ...... le Reuptake Inhibitors (TRIs).

@en

Monoaminergic Antidepressants ...... of Triple Reuptake Inhibitors

@nl

type

Item

label

Monoaminergic Antidepressants ...... le Reuptake Inhibitors (TRIs).

@en

Monoaminergic Antidepressants ...... of Triple Reuptake Inhibitors

@nl

prefLabel

Monoaminergic Antidepressants ...... le Reuptake Inhibitors (TRIs).

@en

Monoaminergic Antidepressants ...... of Triple Reuptake Inhibitors

@nl

P1476

Monoaminergic Antidepressants ...... ple Reuptake Inhibitors (TRIs)

@en

P2093

Alain M. Gardier

http://www.w3.org/2001/XMLSchema#string

Bruno P. Guiard

http://www.w3.org/2001/XMLSchema#string

François Coudore

http://www.w3.org/2001/XMLSchema#string

Guillaume Hache

http://www.w3.org/2001/XMLSchema#string

P2860

Role of central dopamine in pain and analgesia

Duloxetine for treating painful neuropathy or chronic pain

Escitalopram versus other antidepressive agents for depression

Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac)

Descending control of nociception: Specificity, recruitment and plasticity

Observational fear learning involves affective pain system and Cav1.2 Ca2+ channels in ACC

The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties

In vivo effects of the 5-HT(6) antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate

Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor

Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex

P304

285-342

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/PH4020285

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P932

4053958

http://www.w3.org/2001/XMLSchema#string